Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03150329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03150329 · ClinicalTrials.gov record · last posted 2026-08-21

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

StatusActive, Not Recruiting
PhasePhase 1
Started2017-07-18
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back after a period of improvement or that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of cancer cells to grow and spread. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat and pembrolizumab together may work better than pembrolizumab alone in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma.

Protocol amendment history 1 change detected by DataLookout

2026-08-22
Completion pushed: 2026-07-01 → 2027-06-02
Trial Details
NCT Number NCT03150329
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma +8 more
Enrollment 52 participants
Start Date 2017-07-18
Primary Completion 2023-06-23 (estimated)
Study Completion 2027-06-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-21